Patents from Oncopia Therapeutics Inc. (dba SK Life Science Labs) describe proteolysis targeting chimeric (PROTACs) compounds reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
Researchers from ADT Pharmaceuticals and affiliated organizations have published preclinical data for the pan-RAS inhibitor ADT-007, being developed as an anticancer agent.
A Bristol Myers Squibb Co. patent detailed new substituted phenyl oxooxazolyl piperidine dione molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1), zinc finger protein Helios (IKZF2), Aiolos (IKZF3) and Eos (IKZF4) degradation inducers potentially useful for the treatment of cancer.
Memorial Hospital for Cancer and Allied Diseases and Memorial Sloan Kettering Cancer Center have jointly developed new nonsteroid selective androgen receptor modulators (SARMs) and radiolabeled compounds reported to be useful for the diagnosis and treatment of cancer.
Pleco Therapeutics BV has held a successful pre-IND meeting with the FDA to discuss the continued development of PTX-252, an intravenous formulation designed to treat patients with acute myeloid leukemia (AML).
Hepatocellular carcinoma (HCC) represents about 90% of all cases of liver cancer and has a poor prognosis, with a 5-year survival rate of about 18%. Previous findings had shown that RNA 5-methylcytosine (m5C) plays an important role in HCC progression, where the impairment of ferroptosis plays a crucial role in HCC progression.
Researchers from Guangdong Medical University published data from a study that aimed to identify novel biomarkers that would allow for comprehensive assessment of prognosis and immunotherapy response in patients with testicular germ cell tumors (TGCT).
Investigators from the Ontario Institute for Cancer Research and the University Health Network have synthesized triazolopyridopyrimidine and dihydroimidazopyridopyrimidine derivatives acting as eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer and peripheral neuropathy.
Researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry have divulged EGFR (L858R/T790M/C797S triple mutant) and EGFR (del19/T790M/C797S triple mutant) inhibitors reported to be useful for the treatment of cancer.
RSS
